- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07716605
Effectiveness of Alovera Gel vs 1% Silver Sulfadiazine in Superficial Partial Thickness Burn Patients in Pediatric Population.
This prospective randomized controlled study aims to compare the effectiveness of Aloe vera gel versus 1% silver sulfadiazine in the treatment of superficial and superficial partial-thickness burns in the pediatric population. Burn injuries are among the most common causes of morbidity in children, and optimal topical treatment is important for pain control, prevention of infection, and rapid wound healing.
Pediatric patients presenting with superficial and superficial partial-thickness burns will be enrolled and allocated into two treatment groups. One group will receive topical Aloe vera gel, while the other group will receive 1% silver sulfadiazine dressing according to standard burn care protocols. Patients will be followed regularly to assess wound healing progress, pain, infection rate, duration of healing, frequency of dressing changes, and any treatment-related complications. The primary outcome will be time to complete wound healing, while secondary outcomes will include pain score, infection rate, hospital stay, and scar formation.
Study Overview
Status
Intervention / Treatment
Detailed Description
Burn injuries are a significant cause of morbidity among the pediatric population and require effective topical therapy to promote wound healing, prevent infection, reduce pain, and minimize treatment cost. Silver sulfadiazine 1% cream is commonly used as a standard topical antimicrobial agent for superficial burns; however, delayed wound healing and frequent dressing requirements have encouraged the search for alternative therapies. Aloe vera has demonstrated anti-inflammatory, antimicrobial, soothing, and wound-healing properties in previous studies and may serve as an effective and economical alternative in burn management.
This randomized controlled trial will be conducted at The Children's Hospital & Institute of Child Health Lahore over a duration of one year. A total of 60 pediatric patients aged 1 to 18 years presenting with superficial and superficial partial-thickness burns involving 1% to 25% total body surface area (TBSA) will be enrolled in the study. Patients will be randomly allocated into two groups by coin toss/lottery method. One group will receive topical Aloe vera gel dressing, while the second group will receive 1% silver sulfadiazine dressing. Dressings will be applied three times daily according to institutional burn care protocol.
Patients will be followed for a period of 14 days to assess treatment outcomes. The primary outcome measure will be the degree and rate of re-epithelialization of burn wounds. Secondary outcome measures will include pain relief, infection rate, and cost effectiveness of treatment. Patients with burns deeper than superficial partial-thickness burns, including deep second-degree and third-degree burns, as well as patients requiring surgical intervention or presenting with major associated comorbidities, will be excluded from the study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Punjab Province
-
Lahore, Punjab Province, Pakistan, 54000
- UCHSLahore
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- - Patients aged 1 to 18 years
- Both male and female patients
- Superficial and superficial partial-thickness burns
- Burn extent involving 1% to 25% total body surface area (TBSA)
- Presentation within acute phase of burn injury
Exclusion Criteria:
- - Deep partial-thickness (deep second-degree) or third-degree burns
- Patients requiring surgical intervention (skin grafting)
- Infected burns at presentation
- Patients with major comorbidities affecting wound healing (e.g., immunodeficiency, diabetes mellitus)
- Known hypersensitivity to Aloe vera or silver sulfadiazine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Arm-1: Alovera group
Alovera gel applied 3 times daily until complete repithelization
|
Alovera gel applied 3 times daily until complete repithelization
|
|
Other: Silver sulfadiazine 1% topical cream
Silver sulfadiazine applied 3 times daily until complete repithelization
|
Silver sulfadiazine applied 3 times daily until complete repithelization
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Degree of repithelization
Time Frame: 14 days
|
The primary outcome is the degree and rate of re-epithelialization of superficial and superficial partial-thickness burn wounds in pediatric patients.
Wound healing will be assessed clinically by measuring percentage of wound closure and epithelial regeneration over a follow-up period of 14 days or until complete healing, whichever occurs earlier
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain relief
Time Frame: 14 days
|
Pain relief will be assessed using age-appropriate pain scoring systems (FLACC scale for younger children and Visual Analogue Scale for older children).
Changes in pain scores will be recorded before and after treatment during the 14-day follow-up period.
|
14 days
|
|
Wound Infection
Time Frame: 14 days
|
The incidence of wound infection will be assessed clinically based on signs such as erythema, purulent discharge, increased pain, or fever during the treatment period
|
14 days
|
|
Cost effectiveness
Time Frame: 14 days
|
Cost effectiveness will be evaluated by comparing the total cost of treatment in both groups, including dressing materials, frequency of dressing changes, and overall management expenses during the study period.
|
14 days
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- No/2099/UCHS-CH
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Superficial and Superficial Partial Thickness Burns
-
University of the PhilippinesCommittee on Research Implementation and DevelopmentCompletedSuperficial Partial Thickness BurnsPhilippines
-
J. Peter Rubin, MDUnited States Department of Defense; Synedgen, Inc.Terminated
-
Edixomed LtdTerminatedNitric Oxide Generating Gel Dressing in Patients With Superficial Partial Thickness Wounds (ProNOx2)Superficial Partial Thickness Burn | Skin Graft; ComplicationsUnited Kingdom
-
Cellution BiologicsNot yet recruiting
-
Molnlycke Health Care ABCompletedDeep Partial Thickness Burn | Full Thickness BurnsUnited States
-
Molnlycke Health Care ABRecruitingPartial-thickness BurnUnited States
-
University of TennesseeMedline IndustriesCompletedBurns | Partial-thickness BurnUnited States
-
Nanomedic Technologies Ltd.CompletedPartial Thickness BurnIsrael
-
KeriCure MedicalThe University of Texas Health Science Center at San Antonio; Valleywise Health and other collaboratorsRecruiting
-
KeraNetics, LLCUnited States Department of Defense; Wake Forest UniversityTerminatedPartial-thickness BurnUnited States
Clinical Trials on Alovera gel
-
Starpharma Pty LtdCompletedBacterial VaginosisUnited States
-
Glyciome, LLCBrigham and Women's Hospital; University of Puerto RicoCompletedSensory Perceptual Characteristics | User Acceptability of Gel Delivery SystemUnited States, Puerto Rico
-
Novan, Inc.CompletedAcne VulgarisDominican Republic, Honduras, Panama
-
NFlection Therapeutics, Inc.CompletedNeurofibromatosis 1 | Cutaneous NeurofibromaUnited States
-
Starpharma Pty LtdCompletedRecurrent Bacterial Vaginosis (BV)
-
DermBiont, Inc.Active, not recruiting
-
Universidade Federal do ParaCompletedEffect of an Experimental Gel Containing Copaiba Oil-resin in the Control of Dentin HypersensitivityPain | Dentin Sensitivity | Dentin Desensitizing AgentsBrazil
-
Alcon ResearchCompleted
-
Vyne Therapeutics Inc.TerminatedNon-segmental VitiligoUnited States, Canada
-
Population CouncilCompletedHIV InfectionUnited States